US Stock Insider Trading | Apellis Discloses One Insider Transaction on February 13

K-LinePoet · 2026-03-12T20:15:03+00:00

On February 13, 2026, Apellis executive DeLong Mark Jeffrey sold 368 shares on February 11 at a price of $22.15 per share, for a total amount of approximately $8,152.56. In recent insider trading activity, including buying and selling by other executives and board members, there has been active trading. Apellis is a biopharmaceutical company focused on developing drugs for unmet medical needs.

K-LinePoet

2026-03-12 20:15:03

Abstract generation in progress

On February 13, 2026, Apellis (APLS) disclosed one insider transaction. Executive DeLong Mark Jeffrey sold 368 shares on February 11, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
February 13, 2026	Executive	DeLong Mark Jeffrey	February 11, 2026	Sell	368	22.15	8,152.56
February 5, 2026	Director	Francois Cedric	February 3, 2026	Buy	8,840	3.76	$33,200
January 23, 2026	Executive	Chopas James George	January 22, 2026	Sell	2,064	21.77	$44,900
January 23, 2026	Executive	Baumal Caroline	January 22, 2026	Sell	2,797	21.77	$60,900
January 23, 2026	Executive	Nicholson Nur	January 22, 2026	Sell	7,725	21.77	$168,100
January 23, 2026	Executive	Watson David O.	January 22, 2026	Sell	7,832	21.77	$170,500
January 23, 2026	Executive	DeLong Mark Jeffrey	January 22, 2026	Sell	3,371	21.77	$73,400
January 23, 2026	Director	Francois Cedric	January 22, 2026	Sell	27,200	21.77	$591,800
January 23, 2026	Executive	Sullivan Timothy Eugene	January 22, 2026	Sell	10,300	21.77	$223,900
January 23, 2026	Executive	Deschatelets Pascal	January 22, 2026	Sell	5,928	21.77	$129,000

[Company Information]

Apellis Pharmaceuticals, Inc. was incorporated on September 25, 2009, under Delaware law. The company is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics that inhibit the complement system (a part of the immune system) by targeting the central protein C3 in the complement cascade to treat diseases with high unmet needs. In February 2023, the U.S. Food and Drug Administration (FDA) approved SYFOVRE, the first approved drug for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.